SPONSORS
Interaction Checker
This website was last updated on 1st June 2022 and interactions and content may have changed.
The method we use to produce our drug-drug interaction (DDI) recommendations is outlined below. This method is informed by the comparable methods employed by our sister, award-winning sites for HIV and Hepatitis.
When developing DDI recommendations for an anti-cancer agent we work through the following key stages:
We thoroughly review all relevant published and unpublished data. This includes in-depth analysis of controlled clinical DDI studies, a review of all probe substrate studies and results in order that we can understand the key enzymes and transporters affected.
Following (and, where possible, in advance of) regulatory approval, we thoroughly review both the SmPC and USPI licenses as part of this initial analysis.
We develop a unique recommendation for each drug-drug pair. Drug pairs are rated from Red (do not coadminister) to Green (no DDI expected) and a summary of the rationale behind each recommendation is accessible with a further click. This is based on expert interpretation of all available data and expert predictive pharmacokinetics. The SmPC and USPI licenses often interpret the data differently. When they do, our recommendation reflects the most cautious option, but we consider both and cite both in the recommendation.
All relevant references are accessible with a further click.
We thoroughly quality assure all content before publishing it on the site. This includes multiple checks for scientific, clinical and editorial quality and accuracy.
Once content is published on the site, we carry out ongoing quality assurance, ensuring recommendations are reflective of latest data (including publications, label updates and clinical cases).
Our DDI recommendations are reviewed and composed by expert clinicians and pharmacologists
We extrapolate beyond label information and offer clinical management advice and dose modifications where relevant.
Our DDI recommendations provide comprehensive information, comprising:
We assess both FDA and EMA labels, in addition to published and unpublished data.
We include study details in our DDI recommendations, where applicable.
We are available for FREE and without subscription
